The lipid modification slows that proteolytic cleavage substantially, extending Tesamorelin's circulating half-life and giving the molecule the pharmacokinetic profile suitable for once-daily dosing in the Egrifta clinical setting
CrossRef Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis Cong Liu, Milena Schnke, Enchen Zhou, Zhuang Li, Sander Kooijman, Maritte R Boon, Mikael Larsson, Kristina Wallenius, Niek Dekker, Louise Barlind, Xiao-Rong Peng, Yanan Wang, Patrick C N Rensen Cardiovascular Research.2022
With a 3.33mg/mL concentration, a 2.4mg dose requires 72 units, which needs a 1.0mL (100 unit) syringe
While clinical trial data does not establish anxiety as a recognized side effect, understanding the relationship between Zepbound and mental health symptoms remains important for patients and healthcare providers